---
title: A Phase 2 study to assess the safety and efficacy of SUL-238 in patients with early, untreated Parkinson’s Disease
euct_id: 2025-524674-42-00
phase: Phase 4
status: Recruiting
sponsor: Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S.
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-524674-42-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-524674-42-00"
ctis_last_updated: "2026-04-29T03:43:03.644993422"
source: EU Clinical Trials Information System (CTIS)
---
# A Phase 2 study to assess the safety and efficacy of SUL-238 in patients with early, untreated Parkinson’s Disease

**EU CT Number:** [2025-524674-42-00](https://euclinicaltrials.eu/ctis-public/view/2025-524674-42-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.S.
- **Start Date:** 2026-02-09
- **Completion Date:** 2027-02-08
- **Conditions:** Parkinson’s Disease
- **Interventions:** SUL-238, Identical to test product except without active substance

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- CTC Netherlands B.V., Groningen, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson’s Disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-524674-42-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-524674-42-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-524674-42-00*